Cargando…

The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand

OBJECTIVES: The objectives of this study were to describe the use of pharmacogenetics in clinical practice for the treatment of individuals with human immunodeficiency virus (HIV) infection and to determine the treatment outcomes of HIV-infected patients in whom pharmacogenetic testing was performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushyakanist, Asalaysa, Puangpetch, Apichaya, Sukasem, Chonlaphat, Kiertiburanakul, Sasisopin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640229/
https://www.ncbi.nlm.nih.gov/pubmed/26604812
http://dx.doi.org/10.2147/PGPM.S86444
_version_ 1782400051552714752
author Bushyakanist, Asalaysa
Puangpetch, Apichaya
Sukasem, Chonlaphat
Kiertiburanakul, Sasisopin
author_facet Bushyakanist, Asalaysa
Puangpetch, Apichaya
Sukasem, Chonlaphat
Kiertiburanakul, Sasisopin
author_sort Bushyakanist, Asalaysa
collection PubMed
description OBJECTIVES: The objectives of this study were to describe the use of pharmacogenetics in clinical practice for the treatment of individuals with human immunodeficiency virus (HIV) infection and to determine the treatment outcomes of HIV-infected patients in whom pharmacogenetic testing was performed. METHODS: This study involves a retrospective collection of medical records of HIV-infected patients who attended Ramathibodi Hospital during January 2011 to November 2014 and in whom pharmacogenetic testing was performed. We reviewed patients’ characteristics, reasons for pharmacogenomic testing, results of human leukocyte antigen-B* (HLA-B*) 5701, HLA-B*3505, HLA-B*4001, CYP2B6, and antiretroviral drug (ARV) levels, treatment planning after the physicians were informed the results, and outcome after changing the treatment. RESULTS: A total of 103 HIV-infected patients with a median age of 46 (range, 20–85) years were enrolled, and 68.9% of them were male. The reasons for pharmacogenomic testing were having adverse drug reactions besides rash (37.9%), screening before prescribing ARV (36.9%), choice of next ARV (19.4%), and confirmation of the cause of skin rash (5.8%). After the physicians knew the results, they adjusted the treatment plan including changing the regimens, changing the ARV dose for avoiding toxicity, and stopping ARV. Among 45 patients, side effects, such as dizziness from efavirenz or rash from abacavir, were improved in 96.4%. Among 27 patients, abnormal laboratory results, such as renal insufficiency from tenofovir or anemia from zidovudine, were improved and some returned to normal in 59.3%. HIV RNA was undetectable after treatment adjustment in 94.9%. CONCLUSION: The benefits of pharmacogenetic testing are either guiding the initial drug regimen or individualizing regimen, increasing efficacy, and simultaneously avoiding adverse drug reactions. Use of pharmacogenetic testing in HIV-infected Thai adults should be considered.
format Online
Article
Text
id pubmed-4640229
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46402292015-11-24 The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand Bushyakanist, Asalaysa Puangpetch, Apichaya Sukasem, Chonlaphat Kiertiburanakul, Sasisopin Pharmgenomics Pers Med Original Research OBJECTIVES: The objectives of this study were to describe the use of pharmacogenetics in clinical practice for the treatment of individuals with human immunodeficiency virus (HIV) infection and to determine the treatment outcomes of HIV-infected patients in whom pharmacogenetic testing was performed. METHODS: This study involves a retrospective collection of medical records of HIV-infected patients who attended Ramathibodi Hospital during January 2011 to November 2014 and in whom pharmacogenetic testing was performed. We reviewed patients’ characteristics, reasons for pharmacogenomic testing, results of human leukocyte antigen-B* (HLA-B*) 5701, HLA-B*3505, HLA-B*4001, CYP2B6, and antiretroviral drug (ARV) levels, treatment planning after the physicians were informed the results, and outcome after changing the treatment. RESULTS: A total of 103 HIV-infected patients with a median age of 46 (range, 20–85) years were enrolled, and 68.9% of them were male. The reasons for pharmacogenomic testing were having adverse drug reactions besides rash (37.9%), screening before prescribing ARV (36.9%), choice of next ARV (19.4%), and confirmation of the cause of skin rash (5.8%). After the physicians knew the results, they adjusted the treatment plan including changing the regimens, changing the ARV dose for avoiding toxicity, and stopping ARV. Among 45 patients, side effects, such as dizziness from efavirenz or rash from abacavir, were improved in 96.4%. Among 27 patients, abnormal laboratory results, such as renal insufficiency from tenofovir or anemia from zidovudine, were improved and some returned to normal in 59.3%. HIV RNA was undetectable after treatment adjustment in 94.9%. CONCLUSION: The benefits of pharmacogenetic testing are either guiding the initial drug regimen or individualizing regimen, increasing efficacy, and simultaneously avoiding adverse drug reactions. Use of pharmacogenetic testing in HIV-infected Thai adults should be considered. Dove Medical Press 2015-11-05 /pmc/articles/PMC4640229/ /pubmed/26604812 http://dx.doi.org/10.2147/PGPM.S86444 Text en © 2015 Bushyakanist et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bushyakanist, Asalaysa
Puangpetch, Apichaya
Sukasem, Chonlaphat
Kiertiburanakul, Sasisopin
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title_full The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title_fullStr The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title_full_unstemmed The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title_short The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
title_sort use of pharmacogenetics in clinical practice for the treatment of individuals with hiv infection in thailand
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640229/
https://www.ncbi.nlm.nih.gov/pubmed/26604812
http://dx.doi.org/10.2147/PGPM.S86444
work_keys_str_mv AT bushyakanistasalaysa theuseofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT puangpetchapichaya theuseofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT sukasemchonlaphat theuseofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT kiertiburanakulsasisopin theuseofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT bushyakanistasalaysa useofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT puangpetchapichaya useofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT sukasemchonlaphat useofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand
AT kiertiburanakulsasisopin useofpharmacogeneticsinclinicalpracticeforthetreatmentofindividualswithhivinfectioninthailand